VivoSeq
Oncology

Metastatic Neuroendocrine Tumor

2

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

Metastatic Neuroendocrine Tumor is an early-stage landscape with 2 programs across 1 company. The most active players are Vion Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

94/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Vion Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

Lutetium Lu 177 Dotatate

Advanced Accelerator Applications

Triapine

Vion Pharmaceuticals

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

2programs
Small molecule150%
Radiopharmaceutical150%

Modality classified for 100% of 2 pipeline programs.

Analysis

Trial Status

20

clinical trials

Completed16 · 80%
Active, not recruiting2 · 10%
Recruiting1 · 5%
Terminated1 · 5%

Clinical Trials

Trial Activity

20 trials

Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors
Recruiting·TTata Memorial Hospital·Phase 2·NCT07404176·20 enrolled
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
Active, not recruiting·MMayo Clinic·Phase 1·NCT04040088·20 enrolled
A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT05724108·94 enrolled
Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
Completed·SSamsung Medical Center·Phase 2·NCT01099540·37 enrolled
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00027638
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00610129·25 enrolled
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Completed·National Cancer Institute (NCI)·Phase 2·NCT00075439·90 enrolled
Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors
Completed·LLouisiana State University Health Sciences Center in New Orleans·Phase 2·NCT00590343·23 enrolled
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
Completed·RRoswell Park Cancer Institute·Phase 1·NCT03879694·19 enrolled
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Completed·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT00416767·20 enrolled
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01169649·11 enrolled
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT01253161·29 enrolled
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Completed·National Cancer Institute (NCI)·Phase 2·NCT00131911·93 enrolled
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
Completed·—·Phase 2·NCT00602082·84 enrolled
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
Completed·OOhio State University Comprehensive Cancer Center·Phase 2·NCT00017199
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)